Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L9LS and R21/Matrix-MTM in Malian Infants
NCT06461026Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of L9LS in malaria (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Participants With Local Adverse Events at 7 days, Severity of Local Adverse Events at 7 days and 2 more. Started Aug 2024; status: completed.
02
Drugs
L9LS
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06461026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461026.